Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2012 Results
Date:11/7/2012

30 days, through December 6, 2012.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.  

Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda's regulatory approval strategy or proposed path to approval for tasimelteon; the failure of Vanda's clinical trials to demonstrate the safety and/or efficacy of tasimelteon in the treatment of Non-24-Hour Disorder or Major Depressive Disorder; Vanda's failure to obtain regulatory approval for its products, product candidates or partnered products or to comply with ongoing regulatory requirements; the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the comple
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
2. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
3. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
4. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Vanda Pharmaceuticals Reports First Quarter 2012 Results
9. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies Ltd. ... medical technologies company, is delighted to announce its ... 31, 2015, which includes revenue for three months ... of $264,340. Revenue from advanced wound care product sales ... 2015 increased 24% to $1,742,672 compared to $1,400,065 ...
(Date:5/29/2015)... 29, 2015  Epic Sciences announced today that the ... metastatic castrate resistant prostate cancer patients, at the ... Clinical Oncology. This application expands the investigational utility ... platform to characterize circulating tumor cell (CTC) ... patients have heterogeneous clonal CTC populations harboring separate ...
(Date:5/29/2015)... NEW YORK , May 29, 2015  World-renowned prostate ... evaluates new findings on the benefit of MR/Ultrasound Fusion-Guided ... "Our Prostate Cancer Center at Lenox ... MR/Ultrasound Fusion Biopsy System in New York City ... high and low risk prostate cancers. The use of an ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... 2011 Savvy executives in pharmaceutical commercial functions ... in today,s volatile healthcare environment. Quantitative and qualitative ... for increased resources, justify costs, or signal necessary ... presidents, directors, and managers tasked with right-sizing investment ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... European Medicines Agency (EMA) has granted orphan designation for ... B. Orphan designation in the European Union provides several ... launch and access to the central authorization procedure. ...
Cached Medicine Technology:Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLC's New Database Search Function 2Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy 2
(Date:5/29/2015)... 29, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing, is proud to ... for EKG interpretation of athletes. , ... death during athletic activity. New findings presented in February ... to improve cardiac safety in athletes. Physiologic adaptations in ...
(Date:5/29/2015)... 29, 2015 Thursday, May 21st was the ... from all walks of life came together to raise money ... Day is a campaign dedicated to raising money for children ... and making people laugh, the people at Hands-On Seminars decided ... Here they provided food, fun and laughter to their ...
(Date:5/29/2015)... 2015 Belviq for weight loss ... prescription diet medication. In 2012, the FDA approved ... have a BMI >30. It is also approved ... one additional weight-related health condition such as high blood ... main function for weight loss focuses on the brain’s ...
(Date:5/28/2015)... External Counterpulsation (EECP/ECP) has been used ... United States. There are a growing number of people ... symptoms of angina and these patients are often times ... surgery. , “No option” patients are a sizable cohort ... that is considered unacceptable for heart stent or bypass. ...
(Date:5/28/2015)... May 28, 2015 AMVETS National Executive ... the Commission on Care established by Congress to examine ... veterans. , Appointed to the commission by Mitch McConnell, ... be one of only 15 voting members on the ... and Accountability Act of 2014. The goal of the ...
Breaking Medicine News(10 mins):Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2
... ... TV 4 recently awarded Dr. Michael Macdonald of the Aesthetic Surgery Center ... awards. Dr. Macdonald is one of the few cosmetic surgeons in the ... and Reconstructive Surgery and Head and Neck Surgery. ,With over 20 years ...
... ... of successes in its Wide Format Digital Printing and ID Badge divisions. , ... Memphis, TN (PRWEB) April ... despite the tough economy. The company’s two distinct product divisions, Wide Format Digital Printing ...
... ... 2010 targets in the fight against the disease, World Vision’s End Malaria campaign is leading ... to press American congressional leaders to keep investing in programs that are saving the lives ... ...
... ... rash-inducing plants are growing faster and producing more potent toxins as compared ... create ideal conditions for these poisonous plants, producing larger and faster growth ... plants, the topical reactions become worse and affect a larger population, but ...
... ... or associated risk factors, today introduced ,How Your Brain Can Save Your Heart (And ... has shown to be critical for making permanent lifestyle changes that increase our prospects ... ...
... ... and American Society of Pain Educators to pursue publishing and teaching opportunities. , ... (PRWEB) April 16, 2010 ... management education and producers of PAINWeek ( www.painweek.org ) — the national ...
Cached Medicine News:Health News:Dr. Michael Macdonald Named Best Plastic Surgeon in San Francisco Bay Area 2Health News:Dr. Michael Macdonald Named Best Plastic Surgeon in San Francisco Bay Area 3Health News:LSI Earns 3M Warranty Certification; Gains Federal ID Badge Contracts 2Health News:LSI Earns 3M Warranty Certification; Gains Federal ID Badge Contracts 3Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 2Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 3Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 2Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 3Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 4Health News:HeartCoaches Introduces Brain-Based Strategies for a Healthy Heart 2Health News:HeartCoaches Introduces Brain-Based Strategies for a Healthy Heart 3Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 2Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: